CIPH Ciphergen Biosystems (MM)

Electrophoresis Journal Publication Describes Technology and Use for Biomarker Discovery FREMONT, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (NASDAQ:CIPH) and the American Red Cross scientists report in Electrophoresis, 2005, volume 26, (2005), a novel technology and applications for reducing the concentration differences of proteins in biological liquids. The technology, termed Equalizer(TM) Beads by Ciphergen, employs novel bead- based libraries of combinatorial ligands. The paper describes a method for selective absorption of proteins on these beads for reducing the concentration differences between proteins in serum and enabling detection of low-abundance proteins. This method is rapid, requires only micro-liters of sample, is applicable to a wide variety of biological fluids and is amenable to automation to facilitate biomarker discovery. Although the human plasma proteome is comprised of thousands of different proteins and polypeptides, only a few dozen of them make up 99% of the overall protein mass while thousands of proteins are believed to constitute the remaining 1%. Considerable effort in the field of proteomics has been expended towards identifying these proteins, and then understanding their composition and function in disease processes. Current detection methods have been insufficient to cover the overall dynamic concentration range of proteins in blood. This has been a critical impediment to the detection of proteins that may represent new diagnostic and prognostic indicators or therapeutic targets. "We are excited about this technology and are making it available to scientists through our Biomarker Discovery Center(R) laboratories in the United States, Europe and Asia. Using this new Equalizer process, the increased number of detectable proteins should improve the discovery of pathologically relevant biomarkers in both diagnostic and pharmaceutical applications", stated William E. Rich, Ph.D., Chief Executive Officer of Ciphergen. About Ciphergen Ciphergen is dedicated to the discovery of protein biomarkers and panels of biomarkers and their development into protein molecular diagnostic tests that improve patient care; and to providing collaborative R&D services through its Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research and process proteomics applications. ProteinChip Systems enable protein discovery, validation, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at http://www.ciphergen.com/. Safe Harbor Statement Note Regarding Forward-Looking Statements: For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the usefulness of the Deep Proteome(TM) in the diagnosis of disease, the ability of the Protein Equalizer(R) Technology to discover scientifically useful biomarkers that can improve the understanding of disease mechanisms or act as diagnostic assays, and the ability of Ciphergen's Pattern Track(TM) based proteomics to develop high predictive value multimarker assays. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the fact that lower abundant proteins detected through Protein Equalizer technology may not lead to validated biomarkers of scientific value, and our ability to protect and promote our proprietary technologies. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-Q dated August 9, 2005, for further information regarding these and other risks of the Company's business. NOTE: Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: investor relations, Sue Carruthers of Ciphergen Biosystems, Inc., +1-510-505-2233 Web site: http://www.ciphergen.com/

Copyright